SCHEMBL11973717

SCHEMBL11973717

O=C(O)c1ccnc2c3c(ccc12)-c1ccccc1SN3

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 12/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ KDM4A O75164 3/20 0.46
▸ EGLN1 Q9GZT9 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ HIF1AN Q9NWT6 1/20 0.46
▸ PSMD14 O00487 1/20 0.44
▸ KDM4C Q9H3R0 4/20 0.40
▸ KDM6B O15054 1/20 0.40
▸ KDM6A O15550 1/20 0.40
▸ TET3 O43151 1/20 0.40
▸ KDM4B O94953 1/20 0.40
▸ KDM5C P41229 1/20 0.40
▸ KDM4D Q6B0I6 1/20 0.40
▸ TET2 Q6N021 1/20 0.40
▸ ALKBH5 Q6P6C2 1/20 0.40
▸ TET1 Q8NFU7 1/20 0.40
▸ FTO Q9C0B1 1/20 0.40
▸ KDM2A Q9Y2K7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11973515 0.89 SLC40A1 (0.61) SLC40A1KDM4EKDM4AEGLN1L3MBTL1
SCHEMBL11973454 0.85 SLC40A1 (0.63) SLC40A1
SCHEMBL11973273 0.85 SLC40A1 (0.63) SLC40A1PSMD14
SCHEMBL11973710 0.85 SLC40A1 (0.63) SLC40A1KDM4EPSMD14
SCHEMBL11973826 0.85 KDM4E (0.46) SLC40A1KDM4EKDM4AEGLN1L3MBTL1
SCHEMBL11973237 0.83 SLC40A1 (0.49) SLC40A1KDM4ARAB9A
SCHEMBL11973691 0.79 SLC40A1 (0.55) SLC40A1
SCHEMBL18434792 0.79 SLC40A1 (0.55) SLC40A1KDM4EL3MBTL1
SCHEMBL18434626 0.78 SLC40A1 (0.41) SLC40A1KDM4E
SCHEMBL18434468 0.76 SLC40A1 (0.70) SLC40A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885KDM4E 4215/4885KDM4A 4515/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885KDM4E 4215/4885KDM4A 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback